In connection with the start of the phase 3 trials of PCV21, Sanofi has expanded its alliance with South Korea-based SK Bio, ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...

Pneumococcal pneumonia vaccine is under development for the treatment of pneumonia. It is a conjugate vaccine. It is administered through intramuscular as a liquid formulation. It is a new chemical ...

The following is a summary of “Evaluating Sex Differences in Pneumococcal Disease Burden and Vaccination Effectiveness in ...

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...

The following is a summary of “A nationwide study of two decades of invasive pneumococcal disease in the Faroe Islands, ...

SK Bioscience, Sanofi collaborate on next-gen pneumococcal vaccine development SK Bioscience and Sanofi join forces to ...

Sanofi (SNYNF, SNY) and SK bioscience have entered an expanded agreement to develop, license and commercialize next-generation ...

Conner: Tell us about the new recommendations for the pneumonia vaccine.

French pharma major Sanofi says it has entered into a new chapter of the collaboration with South Korean firm SK bioscience ...

The Office for Transportation Security collaborated with the Department of Health and the House of Representatives to enhance ...